 Home > Biochemistry News > Biotechnology News > Focusing on AI and difficult-to-drug targets AstraZeneca reaches two R&D collaborations

Focusing on AI and difficult-to-drug targets AstraZeneca reaches two R&D collaborations

 Last Update: 2022-02-23
 Source: Internet
 Author: User

Tags

plaquenil dosage lupus

phanes therapeutics

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, AstraZeneca has entered into R&D agreements with BenevolentAI and Scorpion Therapeutics, respectively, to use AI drug development platforms to accelerate the development of new drugs for systemic lupus erythematosus and heart failure, as well as to develop innovative anti-cancer therapies for difficult-to-treat transcription factors

AstraZeneca and BenevolentAI reached a research and development agreement in 2019 to collaborate on the development of innovative treatments for chronic kidney disease and idiopathic pulmonary fibrosis

BenevolentAI's drug discovery platform can be applied to any disease and has the ability to discover a large number of innovative targets

The R&D collaboration with Scorpion Therapeutics will focus on transcription factors, proteins that control the expression of genes and regulate important cellular processes such as cell growth and survival

The collaboration will combine Scorpion's integrated discovery platform and AstraZeneca's expertise in cancer precision medicine development to address the challenge of targeting transcription factors

References:

[1] AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against 'undruggable' targets.

[2] BenevolentAI Announces 3-Year Collaboration Expansion With AstraZeneca Focused On Systemic Lupus Erythematosus And Heart Failure.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.